Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Fraunhofer

Wolfgang Fraunhofer, Shrewsbury, MA US

Patent application numberDescriptionPublished
20090291062PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.11-26-2009
20100172862STABLE ANTIBODY COMPOSITIONS AND METHODS OF STABILIZING SAME - The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.07-08-2010
20100278822STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES - The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.11-04-2010

Wolfgang Fraunhofer, Newton, MA US

Patent application numberDescriptionPublished
20080292642Crystalline anti-human IL-12 antibodies - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.11-27-2008
20090148513Compositions and methods for crystallizing antibodies - The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.06-11-2009
20100034823Crystalline anti-hTNFalpha antibodies - The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.02-11-2010

Patent applications by Wolfgang Fraunhofer, Newton, MA US

Wolfgang Fraunhofer, Gurnee, IL US

Patent application numberDescriptionPublished
20110256135ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY COMPOSITIONS - The present invention relates to stable compositions of anti-NGF antibodies, and antigen-binding fragments thereof, and their uses in the prevention and/or treatment of various diseases and disorders in which NGF activity is detrimental, e.g., pain disorders.10-20-2011